Associate Professor
Dr. Yanling Xiao
Curriculum vitae
Dr. Yanling Xiao studied Medicine and obtained her MD at Tongji Medical University (China). She subsequently carried out her PhD at Oita Medical University (Japan) in the Department of Otolaryngology, under the supervision of Prof. Goro Mogi. After completing her doctoral training, she joined the laboratory of Prof. Jannie Borst at the Netherlands Cancer Institute in 1999, where she progressed from postdoctoral researcher to senior scientist.
In 2013, Dr. Yanling Xiao was appointed Associate Staff Scientist at the Netherlands Cancer Institute. In 2014, she undertook a four-month sabbatical as a visiting faculty member in the laboratory of Prof. Matt van de Rijn at Stanford University. In July 2019, Dr. Yanling Xiao joined the Department of Immunology at the Leiden University Medical Center as Assistant Professor and was promoted to Associate Professor in January 2026.
Publications
-
CD4+ T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell activity in human tumors
Lei X, de Groot DC, Welters MJP, de Wit T, Schrama E, van Eenennaam H, Santegoets SJ, Oosenbrug T, van der Veen A, Vos JL, Zuur CL, de Miranda NFCC, Jacobs H, van der Burg SH, Borst J, Xiao Y.
Cell Mol Immunol. 2024 Apr;21(4):374-392. doi: 10.1038/s41423-024-01133-1. Epub 2024 Feb 21. PMID: 38383773; PMCID: PMC10978876
-
CD4+ helper T cells endow cDC1 with cancer-impeding functions in the human tumor micro-environment
Lei X, Khatri I, de Wit T, de Rink I, Nieuwland M, Kerkhoven R, van Eenennaam H, Sun C, Garg AD, Borst J, Xiao Y
Nat Commun. 2023 Jan 13;14(1):217. doi: 10.1038/s41467-022-35615-5. PMID: 36639382; PMCID: PMC9839676.
-
Immune checkpoints targeting dendritic cells for antibody-based modulation in cancer
Lei X, Wang Y, Broens C, Borst J, Xiao Y
Int Rev Cell Mol Biol. 2024;382:145-179. doi: 10.1016/bs.ircmb.2023.07.006. Epub 2023 Aug 12. PMID: 38225102.
-
Bone marrow-derived myeloid progenitors as driver mutation carriers in high- and low-risk Langerhans cell histiocytosis
Xiao Y, van Halteren AGS, Lei X, Borst J, Steenwijk E, de Wit T, Grabowska J, Voogd R, Kemps P, Picarsic J, van den Bos C, Borst J
Blood. 2020 Nov 5;136(19):2188-2199. doi: 10.1182/blood.2020005209. PMID: 32750121.
-
CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1
Miao B, Hu Z, Mezzadra R, Hoeijmakers L, Fauster A, Du S, Yang Z, Sator-Schmitt M, Engel H, Li X, Broderick C, (..) Xiao Y, Heck AJR, Guan W, Lowe SW, Horlings HM, Wang C, Brummelkamp TR, Blank CU, Schumacher TNM, Sun C
Cancer Cell. 2023 Oct 9;41(10):1817-1828.e9. doi: 10.1016/j.ccell.2023.08.008. Epub 2023 Sep 7. PMID: 37683639; PMCID: PMC11113010.
